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THE CALCIUM ANTAGONIST nifedipine has been shown during the last decade to be effective in the treatment of angina pectoris' and more recently in the treatment of hypertension2 and heart failure.3 A cardioprotective effect of nifedipine has also been demonstrated after experimental coronary occlusion.4 6 There are several reasons why nifedipine might limit myocardial damage in patients with acute myocardial infarction (AMI). By reducing systemic vascular resistance, nifedipine might improve left ventricular unloading and reduce left ventricular workload.7 Dilatation of coronary arteries9 10 might enhance collateral flow to the ischemic region and possibly restore blood flow in situations in which spasm contributes to the ischemia. " Furthermore, nifedipine might inhibit detrimental cellular uptake of Ca ++ during ischemia. 2 This trial was primarily designed to investigate whether early intervention with nifedipine in AMI might reduce infarct size, as determined enzymatically by measurement of creatine kinase isoenzyme MB (CK-MB) levels. The amount of increase in serum level of this enzyme has been shown to have a close relationship to infarct size. '3 14 Methods Patient selection and recruitment. All patients who were admitted to the four participating hospitals with suspected AMI during the trial period (885 patients) were screened for inclusion. Inclusion criteria were (1) severe central chest pain for at least 30 min, continuing on admission or until an analgesic was given, or (2) electrocardiographic changes suggesting an AMI (not previously recognized ST segment elevation >0.2 mV in precordial leads or >0.1 mV in extremity leads, or a Q wave >-0.04 sec that had not been previously recognized). These inclusion criteria were fulfilled by 623 patients, 396 (64%) of whom were excluded (table 1) .
Allocation and treatment. After informed consent was obtained, eligible patients of both sexes were randomly assigned to treatment with either nifedipine (10 mg capsules) or placebo. Patients at each center were assigned in blocks of 10 and given capsules from prenumbered bottles. A patient was considered to be included in the trial when he or she took the first capsule sublingually. Subsequent doses were 10 mg orally and were begun 30 min after the first dose unless systolic blood pressure was below 90 mm Hg. For the first 2 days 10 mg was given five Estimation of sample size. The study was designed so that there would be a 90% chance of detecting a 30% reduction in infarct size by nifedipine. The probability of obtaining a falsepositive result was 5%. Determination of infarct size was the primary end point of the trial. The coefficient of variation for infarct size was estimated to be about 50% so that about 120 patients with infarcts of calculable size were required. However, to allow for patients who might be found not to have AMI and for patients whose infarct size could not be calculated, the goal for recruitment was set at 230 patients.
Analysis of results. Classification of infarct class (A to C), infarct sites, Kd determinations, and causes of death was done blindly with respect to treatment group. Data were analyzed by the study coordinator (P. A. S.). Mortality was analyzed with a life table method. Continuous variables were reported as mean + SD, unless otherwise stated. Standard textbook methods (parametric and nonparametric) were used as appropriate for the comparison of treatment effects. All statistical methods were based on two-sided tests, and p less than .05 was considered the level of significance.
Results
Trial population. Of the 227 patients who were randomly assigned treatment, 1 12 received nifedipine and 1 15 placebo. In five patients, two of whom received nifedipine, the protocol was violated; one had been receiving verapamil and in four the start of treatment was more than 12 hr after onset of symptoms. Of these five patients, one nifedipine and one placebo patient developed AMI.
Of the remaining 222 patients, the diagnosis of AMI (class A or B) was confirmed in 74 (67%) of 110 nifedipine patients and 83 (74%) of 112 placebo patients. In the population as a whole treatment was initiated a mean 5.2 + 3.0 hr after onset of symptoms, with a median value of 4 hr and 10 min. However, nifedipine patients with AMI were included slightly later than placebo patients with AMI (5.48 + 2.86 vs 4.62 ± 2.80 hr after onset of symptoms in the nifedipine and placebo groups, respectively; t = 1.9, p = .059). Other baseline characteristics are listed in Enzyme analysis. Class A myocardial infarction (see Methods) was diagnosed in 67 of 110 nifedipine patients and in 76 of 112 placebo patients (NS) and class B myocardial infarction was diagnosed in seven patients in each treatment group.
The calculation of accumulated CK-MB release was impossible in three nifedipine and in six placebo patients because of death before the peak CK-MB level was reached or an insufficient number of CK-MB samples.
The distribution of the times from onset of symptoms until peak CK-MB level was reached is shown in figure 2 . The mean values were 22.5 + 14.9 hr in the nifedipine group vs 22.1 + 9.4 hr in the placebo group (NS). Peak CK-MB level was reached before 20 hr in 46% of nifedipine patients and in 38% of placebo pa- (9) 43 (5) Numbers in parentheses denote adverse reactions that resulted in temporary or permanent interruption of treatment.
tients (NS). Kds could be calculated from the declining part of the CK-MB curve in 60 patients in each group and were nearly identical (nifedipine group, 0.0485 ± 0.01 22/hr; placebo group, 0.0487 ± 0.01 1 1 /hr; NS). A common Kd value of 0.0486/hr was used for 11 nifedipine and in 17 placebo patients.
The evolution of the CK-MB release in the two groups is illustrated in figure 3 . Although patients in the nifedipine group generally had larger mean CK-MB values than those in the placebo group more than 16 hr after onset, this difference did not reach statistical significance. Calculated infarct size index (ISI; CK-MB geq/m2) was diac or hypotensive response to the treatmen tendency towards larger ISIs.
Clinical parameters. After the first dose of mean systolic blood pressure decreased fron to 135 ± 28 mm Hg (p < .01), but it did i after the first placebo dose (table 5) . Th corresponding increase in heart rate from 7 79 + 19 beats/min (p < .01) vs no cha placebo group. These differences were als after the later doses, but at discharge fro there were no significant differences betwe groups with respect to heart rate or bloo (table 6 ).
An initial systolic blood pressure of 160 more was recorded in 30 nifedipine and patients with AMI. After two doses the sys pressure haddeclined from 174 ± 21 to 144
Hg in hypertensive patients on nifedipine, 175 ± 18 to 162 ± 26 mm Hg in hypertensive patients on placebo (p < .01 for nifedipine compared with placebo patients). In patients with AMI a systolic placebo blood pressure less than 90 mm Hg after the first two doses was noted in 29% of nifedipine-treated vs 18% of placebo-treated patients (NS).
The rate of occurrence of serious arrhythmias and conduction defects was similar in the two groups. There were no significant differences in the prevalence of reported angina pectoris or heart failure at discharge. Morphine requirements were similar in the two *56 *4 groups, but the mean dosage of furosemide necessary 
Discussion
The optimistic expectations that nifedipine therapy would reduce infarct size were not fulfilled in the present study. This might have been the result of methodologic problems, e.g., an inadequate sample size. A revised calculation of statistical power with the use of the mean and SD of the ISI in the placebo group reveals there was a probability of greater than 0.90 of detecting an infarct size reduction of 30% by nifedipine. However, the chance of having missed a 20% reduction was 0.37.
With respect to adverse reactions, it seems that nifedipine is reasonably well tolerated in patients with suspected AMI. The present study confirms previous reports2 of nifedipine as an efficacious antihypertensive agent. However, normalization of the blood pressure by nifedipine in the subgroup with initial hypertension was not associated with any reduction in infarct size. The results indicate that nifedipine was unable to reduce ischemic pain in patients with AMI. Reduced need for furosemide in the nifedipine-treated patients, in spite of a tendency to large enzyme values, may be an indication of a beneficial effect on heart failure. However, increased furosemide use in placebo patients may also be due to the higher proportion of patients with pulmonary rales on entry in this group (table 2) .
The two groups were comparable with respect to baseline characteristics, but it is noteworthy that among patients with AMI /3-receptor blockers were used before entry in only 13% of nifedipine patients compared with in 21% of placebo patients. Since /-receptor blockers may reduce infarct size, 15 this might introduce a bias favoring the placebo group. The combination of /3-receptor blocker and nifedipine was not associated with reduced infarct size in the present study, but the number of patients on this combination was too small to evaluate the efficacy of this combination for limitation of infarct size.
The mean delay from onset of symptoms to the initiation of treatment was 5.5 ± 2.9 hr in the nifedipine group. This delay may have been important since myocardial injury is believed to be irreversible after 4 to 6 hr of grave ischemia.'6 However, there was no trend toward smaller ISI in the subgroup of 20 patients on nifedipine treated before 3 hr after onset of symptoms (table 4) .
There have been some objections to the use of calculated enzyme release as an indicator of myocardial infarct size,'7 but several studies have shown a good correlation with autopsy assessments.'3. 4 1 Since the measured Kd was nearly identical in the two groups, it is not likely that nifedipine had any influence on CK-MB degradation. Increased flow to the infarct area might possibly increase the proportion of enzyme that is washed out. Early reperfusion with streptokinase has been associated with earlier and higher CK-MB 642 CIRCULATION peaks,'9 but the correlation between the enzymatic and histologic infarct size is apparently not greatly influenced unless reperfusion occurs very early (<2 hr) after the occlusion. 19 There was a slight tendency towards earlier and higher peaks in the nifedipine group in the present study (figure 2), but this was not significantly different from that in the placebo group. Still, the possibility of increased washout of enzyme cannot be ruled out in the present trial. The graph of the evolution of CK-MB release (figure 3) shows a general, but nonsignificant, trend toward larger infarct size in the nifedipine group. This trend was especially pronounced in some nifedipine subgroups (table 4) including those of patients with initial hypertension, patients with hypotension or a reduction in systolic blood pressure of more than 10%, and patients with an increase in heart rate of more than 10 beats/min after the first two doses. When tested individually with a rank-sum test, these differences are significant at p < .05, but caution should be exercised in claiming any significance of results of multiple retrospective subgroup analysis. One explanation for the increased ISI in some subgroups is that a chance predominance of patients with large infarctions in the nifedipine group would lead to an increased frequency of heart failure, with tachycardia and hypotension being the result, and not the cause, of large infarctions.
From the subgroup analysis in the present study it might be hypothesized that nifedipine increases infarct size in some patients. An increased heart rate could reduce coronary perfusion time and increase oxygen demands and hypotension might reduce coronary perfusion pressure and thereby coronary flow if the resistant vessels are maximally dilated. These effects of nifedipine might have outweighed its beneficial effects on collateral flow and resistance to ischemia. It is evident from the changes in heart rate and blood pressure observed that amounts of nifedipine sufficient to produce systemic hemodynamic changes were given in the present study. A 4 , October 1984 oses. 23 The experimental evidence for a steal effect of nifedipine seems conflicting,5' 9, 24. 25 but there are several reports of nifedipine-induced ischemia in humans. , 26 If the action of the drug is dependent on the presence of collaterals, limitation of infarct size most likely would be expected in patients with prior symptomatic coronary heart disease. Although the present study shows a slight tendency towards larger ISIs in patients without prior symptomatic coronary heart disease, this difference is not significant. The favorable effect of nifedipine on acute ischemic injury in experimental preparations4-6 may be due to a better collateral circulation in dogs than in humans; the findings in dogs could not be reproduced in species like the baboon with poorly developed collateral circulation,27 thus supporting results of the present study in humans.
Preliminary results from a study in which another calcium antagonist (verapamil) was used in patients with AMI are now available. 28 In 1436 patients with AMI randomly assigned to verapamil or placebo, there was no effect of the drug on 6 month survival and infarct size was also similar in a subgroup of 100 patients in whom it was assessed by serial creatine kinase analysis. 29 In a recent double-blind study, Muller et al. 30 investigated the effects of nifedipine in 191 patients with threatened or established AMI. Their dosage of nifedipine was larger than that in the present study, but the effects on infarct size and 6 month mortality were similar.
As yet, there is no reason to recommend general treatment with calcium antagonists to reduce infarct size.
